Advances in antibody-drug conjugates for gynecologic malignancies-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Advances in antibody-drug conjugates for gynecologic malignancies

Published:2022-12-08 Issue:1 Volume:35 Page:6-14
ISSN:1040-872X
Container-title:Current Opinion in Obstetrics & Gynecology
language:en
Short-container-title:

Author:

Tymon-Rosario Joan,Gorman Megan,Richardson Debra L.,Washington Christina,Santin Alessandro D.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Obstetrics and Gynecology

Reference41 articles.

1. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study;Coleman;Lancet Oncol,2021

2. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma;Zhao;Proc Natl Acad Sci USA,2013

3. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice;Buza;Mod Pathol,2013

4. Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu;Fader;J Clin Oncol,2018

5. A multihistology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers;Li;J Clin Oncol,2018

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Updates in the Use of Targeted Therapies for Gynecologic Cancers;American Society of Clinical Oncology Educational Book;2024-06

2. Ocular toxicities associated with antibody drug conjugates;Current Opinion in Ophthalmology;2024-05-31

3. Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer;International Journal of Gynecologic Cancer;2023-12-14

4. Fam-Trastuzumab Deruxtecan in HER2/Neu-Expressing Serous Endometrial Cancer;JCO Precision Oncology;2023-08

5. Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer;Expert Review of Anticancer Therapy;2023-07-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3